Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
26
MDRX Quote, Financials, Valuation and Earnings
Last price:
$4.50
Seasonality move
:
-0.37%
Day range:
$4.15 - $5.05
52-week range:
$3.00 - $10.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.83x
P/B ratio:
0.48x
Volume:
13.9K
Avg. volume:
186.7K
1-year change:
-51.61%
Market cap:
$487.2M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDRX
Veradigm, Inc.
|
$144M | $0.05 | -- | -- | $5.83 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$4.6M | -$0.69 | -7.14% | -109.39% | $53.71 |
|
LFMD
LifeMD, Inc.
|
$62.1M | $0.05 | -24.41% | -93.33% | $9.25 |
|
STRM
Streamline Health Solutions,
|
$5.3M | -- | -24.87% | -- | $22.50 |
|
TBRG
TruBridge, Inc.
|
$85.6M | $0.47 | 0.28% | -28.23% | $22.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDRX
Veradigm, Inc.
|
$4.50 | $5.83 | $487.2M | -- | $0.00 | 0% | 0.83x |
|
CDT
CDT Equity, Inc.
|
$1.57 | -- | $2.6M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$17.14 | $53.71 | $536.3M | -- | $1.03 | 0% | 27.34x |
|
LFMD
LifeMD, Inc.
|
$4.00 | $9.25 | $192.5M | -- | $0.00 | 0% | 0.71x |
|
STRM
Streamline Health Solutions,
|
$5.34 | $22.50 | $23.3M | -- | $0.00 | 0% | 1.18x |
|
TBRG
TruBridge, Inc.
|
$22.06 | $22.60 | $331.1M | 118.35x | $0.00 | 0% | 0.92x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDRX
Veradigm, Inc.
|
-- | 0.909 | -- | -- |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.945 | 27% | 1.13x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.080 | 0.07% | 12.39x |
|
LFMD
LifeMD, Inc.
|
83.24% | 3.242 | 2.29% | 0.58x |
|
STRM
Streamline Health Solutions,
|
55.84% | 4.014 | 109.22% | 0.25x |
|
TBRG
TruBridge, Inc.
|
48.06% | -0.588 | 55.15% | 1.44x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDRX
Veradigm, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LFMD
LifeMD, Inc.
|
$50M | -$2M | -15.29% | -- | -3.27% | -$3.7M |
|
STRM
Streamline Health Solutions,
|
$2.6M | -$1.1M | -33.65% | -64.34% | -22.91% | -$1.2M |
|
TBRG
TruBridge, Inc.
|
$37.3M | $7.8M | 0.81% | 1.61% | 9.01% | $9.3M |
Veradigm, Inc. vs. Competitors
-
Which has Higher Returns MDRX or CDT?
CDT Equity, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of --. Veradigm, Inc.'s return on equity of -- beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDRXVeradigm, Inc.-- -- -- CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About MDRX or CDT?
Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 29.63%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Veradigm, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Veradigm, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDRXVeradigm, Inc.1 2 0 CDTCDT Equity, Inc.0 0 0 -
Is MDRX or CDT More Risky?
Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDRX or CDT?
Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDRX or CDT?
Veradigm, Inc. quarterly revenues are --, which are smaller than CDT Equity, Inc. quarterly revenues of --. Veradigm, Inc.'s net income of -- is lower than CDT Equity, Inc.'s net income of -$7.1M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.83x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDRXVeradigm, Inc.0.83x -- -- -- CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns MDRX or LENZ?
LENZ Therapeutics, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of -133.6%. Veradigm, Inc.'s return on equity of -- beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital MDRXVeradigm, Inc.-- -- -- LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About MDRX or LENZ?
Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 29.63%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $53.71 which suggests that it could grow by 213.39%. Given that LENZ Therapeutics, Inc. has higher upside potential than Veradigm, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Veradigm, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDRXVeradigm, Inc.1 2 0 LENZLENZ Therapeutics, Inc.6 0 0 -
Is MDRX or LENZ More Risky?
Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDRX or LENZ?
Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Veradigm, Inc. pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDRX or LENZ?
Veradigm, Inc. quarterly revenues are --, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. Veradigm, Inc.'s net income of -- is lower than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.83x versus 27.34x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDRXVeradigm, Inc.0.83x -- -- -- LENZLENZ Therapeutics, Inc.27.34x -- $12.5M -$16.7M
-
Which has Higher Returns MDRX or LFMD?
LifeMD, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of -5.91%. Veradigm, Inc.'s return on equity of -- beat LifeMD, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDRXVeradigm, Inc.-- -- -- LFMDLifeMD, Inc.83.06% -$0.10 $9.9M -
What do Analysts Say About MDRX or LFMD?
Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 29.63%. On the other hand LifeMD, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 131.25%. Given that LifeMD, Inc. has higher upside potential than Veradigm, Inc., analysts believe LifeMD, Inc. is more attractive than Veradigm, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDRXVeradigm, Inc.1 2 0 LFMDLifeMD, Inc.7 1 0 -
Is MDRX or LFMD More Risky?
Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison LifeMD, Inc. has a beta of 1.363, suggesting its more volatile than the S&P 500 by 36.256%.
-
Which is a Better Dividend Stock MDRX or LFMD?
Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. LifeMD, Inc. pays out 16.59% of its earnings as a dividend. LifeMD, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDRX or LFMD?
Veradigm, Inc. quarterly revenues are --, which are smaller than LifeMD, Inc. quarterly revenues of $60.2M. Veradigm, Inc.'s net income of -- is lower than LifeMD, Inc.'s net income of -$3.6M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while LifeMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.83x versus 0.71x for LifeMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDRXVeradigm, Inc.0.83x -- -- -- LFMDLifeMD, Inc.0.71x -- $60.2M -$3.6M
-
Which has Higher Returns MDRX or STRM?
Streamline Health Solutions, has a net margin of -- compared to Veradigm, Inc.'s net margin of -34.2%. Veradigm, Inc.'s return on equity of -- beat Streamline Health Solutions,'s return on equity of -64.34%.
Company Gross Margin Earnings Per Share Invested Capital MDRXVeradigm, Inc.-- -- -- STRMStreamline Health Solutions,53.85% -$0.40 $25M -
What do Analysts Say About MDRX or STRM?
Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 29.63%. On the other hand Streamline Health Solutions, has an analysts' consensus of $22.50 which suggests that it could fall by -71.91%. Given that Veradigm, Inc. has higher upside potential than Streamline Health Solutions,, analysts believe Veradigm, Inc. is more attractive than Streamline Health Solutions,.
Company Buy Ratings Hold Ratings Sell Ratings MDRXVeradigm, Inc.1 2 0 STRMStreamline Health Solutions,1 0 0 -
Is MDRX or STRM More Risky?
Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison Streamline Health Solutions, has a beta of 2.070, suggesting its more volatile than the S&P 500 by 106.993%.
-
Which is a Better Dividend Stock MDRX or STRM?
Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions, offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. Streamline Health Solutions, pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDRX or STRM?
Veradigm, Inc. quarterly revenues are --, which are smaller than Streamline Health Solutions, quarterly revenues of $4.8M. Veradigm, Inc.'s net income of -- is lower than Streamline Health Solutions,'s net income of -$1.6M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while Streamline Health Solutions,'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.83x versus 1.18x for Streamline Health Solutions,. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDRXVeradigm, Inc.0.83x -- -- -- STRMStreamline Health Solutions,1.18x -- $4.8M -$1.6M
-
Which has Higher Returns MDRX or TBRG?
TruBridge, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of 6.3%. Veradigm, Inc.'s return on equity of -- beat TruBridge, Inc.'s return on equity of 1.61%.
Company Gross Margin Earnings Per Share Invested Capital MDRXVeradigm, Inc.-- -- -- TBRGTruBridge, Inc.43.35% $0.37 $347.2M -
What do Analysts Say About MDRX or TBRG?
Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 29.63%. On the other hand TruBridge, Inc. has an analysts' consensus of $22.60 which suggests that it could grow by 2.45%. Given that Veradigm, Inc. has higher upside potential than TruBridge, Inc., analysts believe Veradigm, Inc. is more attractive than TruBridge, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDRXVeradigm, Inc.1 2 0 TBRGTruBridge, Inc.2 3 0 -
Is MDRX or TBRG More Risky?
Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison TruBridge, Inc. has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.93%.
-
Which is a Better Dividend Stock MDRX or TBRG?
Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. TruBridge, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDRX or TBRG?
Veradigm, Inc. quarterly revenues are --, which are smaller than TruBridge, Inc. quarterly revenues of $86.1M. Veradigm, Inc.'s net income of -- is lower than TruBridge, Inc.'s net income of $5.4M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while TruBridge, Inc.'s PE ratio is 118.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.83x versus 0.92x for TruBridge, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDRXVeradigm, Inc.0.83x -- -- -- TBRGTruBridge, Inc.0.92x 118.35x $86.1M $5.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
